Overview

A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard treatments.
Phase:
Early Phase 1
Details
Lead Sponsor:
Zhejiang University
Collaborator:
Shanghai OriginCell Therapeutics Co., Ltd.